# Transcode Therapeutics, Inc.: overview RNAZ · Nasdaq · CIK 1829635 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/rnaz.md) · [Financials](/companies/rnaz/financials.md) · [Filings](/companies/rnaz/filings.md) · [Insiders](/companies/rnaz/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(146.06)](/filings/0001829635-25-000004.md) | not reported | [(70.16)](/filings/0001104659-26-062535.md) | [(5.13)](/filings/0001829635-26-000003.md) | [(5.82)](/filings/0001829635-25-000004.md) | not reported | [(21.28)](/filings/0001104659-26-062535.md) | [(7.17)](/filings/0001829635-26-000003.md) | | Free cash flow | $k | [(3,925) d](/filings/0001829635-25-000004.md) | [(3,147) d](/filings/0001104659-26-043810.md) | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.81)](/filings/0001104659-23-040158.md) | [(1082.79)](/filings/0001410578-24-000413.md) | [(3419.01)](/filings/0001558370-25-004843.md) | [(1336.63)](/filings/0001104659-26-043810.md) | [(52.59)](/filings/0001104659-26-043810.md) | | Free cash flow | $m | [(5.5)](/filings/0001104659-23-040158.md) | [(15.9)](/filings/0001410578-24-000413.md) | [(18.1)](/filings/0001558370-25-004843.md) | [(13.4)](/filings/0001104659-26-043810.md) | [(19.5)](/filings/0001104659-26-043810.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/rnaz/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Yorkville Advisors Global, LP](/funds/1838613.md) | 2026-06-30 | $122.0k | 19,639 | | New +19,639 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $40.6k | 6,545 | | Unchanged | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $18.5k | 2,982 | | Unchanged | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $17.9k | 2,888 | | Reduced −5,407 | | [FMR LLC](/funds/315066.md) | 2026-06-30 | $4.4k | 706 | | New +706 | | [Tower Research Capital LLC (TRC)](/funds/1533421.md) | 2026-06-30 | $4.2k | 677 | | Added +449 | | [WELLS FARGO & COMPANY/MN](/funds/72971.md) | 2026-06-30 | $342 | 55 | | Unchanged | | [SBI Securities Co., Ltd.](/funds/1851815.md) | 2026-06-30 | $75 | 12 | | Unchanged | ## Recent filings [All 321 filings](/companies/rnaz/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-01 | 20:05 ET | [8-K](/filings/0001104659-26-112826.md) | 1.01 Entry into a material agreement; 2.04 Item not in the standard list | 0001104659-26-112826 | | 2026-09-28 | 12:16 ET | [8-K](/filings/0001104659-26-111170.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-111170 | | 2026-09-11 | 21:00 ET | [8-K](/filings/0001104659-26-107115.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001104659-26-107115 | | 2026-08-14 | 21:05 ET | [10-Q](/filings/0001829635-26-000003.md) | Quarterly report, period 2026-06-30 | 0001829635-26-000003 | | 2026-08-03 | 20:38 ET | [SCHEDULE 13D/A](/filings/0001104659-26-089819.md) | Ownership report, active investor, amended | 0001104659-26-089819 | | 2026-08-03 | 20:15 ET | [8-K](/filings/0001104659-26-089805.md) | 3.03 Change to security holders’ rights; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001104659-26-089805 | | 2026-07-27 | 20:15 ET | [SCHEDULE 13D/A](/filings/0001104659-26-087098.md) | Ownership report, active investor, amended | 0001104659-26-087098 | | 2026-07-23 | 20:15 ET | [SCHEDULE 13D/A](/filings/0001104659-26-086266.md) | Ownership report, active investor, amended | 0001104659-26-086266 | | 2026-07-20 | 20:15 ET | [8-K](/filings/0001104659-26-085073.md) | 5.07 Shareholder vote results | 0001104659-26-085073 | | 2026-07-17 | 20:15 ET | [SCHEDULE 13D/A](/filings/0001104659-26-084636.md) | Ownership report, active investor, amended | 0001104659-26-084636 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-043810.md), filed Apr 15, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1829635 - Tickers: RNAZ - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.